Načítá se...
Ciglitazone, a PPARγ agonist, ameliorates diabetic nephropathy in part through homocysteine clearance
Diabetes and hyperhomocysteinemia (HHcy) are two independent risk factors for glomeruloslerosis and renal insufficiency. Although PPARγ agonists such as ciglitazone (CZ) are known to modulate diabetic nephropathy, the role of CZ in diabetes-associated HHcy and renopathy is incompletely defined. We t...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Physiological Society
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2584817/ https://ncbi.nlm.nih.gov/pubmed/18780770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.90534.2008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|